Icon

Olux E - (0.05% Aerosol, Foam; Topical)

Clobetasol Propionate Delcor Pharma
0.05% Aerosol, Foam; Topical
Less Than $1000 mn
Less Than 5
Less Than 5
None None
Less Than 5
Less Than 5
Olux-E (clobetasol propionate foam) Foam is indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 12 years of age or older
Yes
******* *** *** ***** ** **** **** ** **** ******* *******- **** *, **** & *******-**** *, **** *** *** ************ *********. ****** *** ****** ** ** ****** ****, ********** *** ******* **** *******, ********* ** *** ***** ** ***** ******* ******** *** ******* ** *** ****. ******* **** **** ***** **** ** ** *** **** ******* *** *** ************ *********. ****** *** ****** ** ** ****** ****, ********** *** ******* **** **** ** **** ***** *** ***** ** ********** *** *** ***** *** ** ****** **** *** ****** ******* **** ********. **** **** ** * *** *********** *********** *** ******* *** **** **** **** *, ****.
Olux E Patent 1 Patent 2 Patent 3 Patent 4
******* ******* ******* ******* *******
*** (****) ******* ******* ******* *******
******** ******* ******* ******* *******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
******* *** \ *** *** **** ******* ******** ******** ** *** ****
*** (****) ** \ ** *** *, **** ******* ******** *** ****** *******
******** ** \ ** *** **, **** ******* ******** ******** ** **** **, ****
  1. ****, **** : ******* ******** ******* ***** *** **** ** **** *.**% **** **** *** ****** ******* , *******.
  2. ****, **** : ******* ***** **** ******* ******* ** ******** ***** ** ********.
  3. *** *, **** : ********** *** ********* **** ******* ***** *** ***** ** ********* *** *** *****.
  4. *** *, **** : ******* ******** **** *.
  5. *** **, **** : **** ******** ****** ***** *** **** ** **** ******* '*** & '*** **** ******** ** **** *, ****.
  6. *** *, **** : ****** ***** * ********** ******* **** ** ******** ***** ** ********.
  7. *** **, **** : ********** *** ********* **** *** (****) ***** *** ***** ** ********* *** *** *****.
  8. *** **, **** : ****** ***** * **** ******* ******** **** ****** ******* (**** *, ****).
  9. *** **, **** : ********** ********* **** ******** *** ***** ** *** ********* *** *******.

Download ParaIV Report


Download ParaIV Detailed Report


To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.